The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
following takeda results , hutchmed could have informed shareholders about first quarter payment from takeda, arising from fru*****inib global sales. also, anticipated annual earnings from fru*****inib global (specifically in usa) sales would have helped to maintain a stable share price. even now, it is not too late for releasing news about earnings as well as an update about approvals from european and japanese authorities.
Moving to FTSE 250 list was discussed in the past.
2 -3 years ago, I had emailed the company asking if the management was considering such a move. I had quoted the advantages often discussed on this forum, such as getting wider publicity and attracting investments from major funds. Mr Hogg, then CEO, had replied that the company was aware of the potential of such a move, but they had other priorities. Is it correct, moving to the main market would include expensive administrative affair?
ss aka hcms, agree with you. it’s been good two to three consecutive weeks for hcm. hopefully, we are approaching towards the brighter end of the tunnel. last two years had been rough ride for the long term shareholders. over the other side of world, experience of investors who joined during hkse listing of “lucky” 0013 has been not so pleasant either. in spite of the recent progress, friday’s closing sp is well behind the listing price (?hkse40).
i was reading recent posts on adv.n from 1jat (?a.k.a jatw). the company is cash rich and a dividend of 10p per share/ hk$ 1 is possible, provided the management wishes to express their gratitude towards the shareholders. however, the company has passed a resolution in its agm giving right to the directors to buy back the shares. which is better, buy back scheme or a first ever dividend?
takeda’s financial figures (fru*****inib sales) are very encouraging. is hcm obliged to release a statement quoting the actual payment /profit resulting from fruq… golbal sales ? that should help shareholders to understand the actual profit from that source.
thanks to jatw for the informative posts.
Remember reading a post from Jatw about Takeda’s results, scheduled for tomorrow, 9th May.
Any predictions about profit from fruq..sales, ex-China and income to HCM?
Points of interest to HCM shareholders will be;
-progress Takeda has achieved with fruq.. sales in the USA
-expected date of approval for Fruq..from European medical agency (received a positive opinion from CHMP, recently).
Perhaps, the ‘analysts’ in London and US were unable to ‘analyse’ CHMP’s POSITIVE opinion about fruq….
This morning, they seemed to have realised the meaning of ‘positive opinion’, of course, after getting a clue from HK.
Thanks again for a detailed explanation and for emailing the investors’ relations at HCM. Hope they respond to your query. (In my experience, getting a response from the IR is not as straightforward as it used to be during Mr Hogg’s period)
Waiting for Takeda’s results scheduled for 9th May.
On a day, when the company gives some favourable news the sp, generally if not invariably, achieves downward trajectory. Today, in the absence of any news, it’s gone up by 7-8% both at HKSE and LSE. Nearly 45k AIM shares traded within the first hour. Not a big rise in the sp but it’s not negligible either.
Any reason/s?
An opportunity to showcase their entire ‘assets’ in a major venue. Nice efforts by the team to display their poster presentations. Keenly waiting to see the final results from the global Multi centre clinical trials for surufatinib.
Thank you Jatw for your opinion.
More than 20 year old “budding” pharma company. based in a country with stable governance and economy. 5000 personnel with 1200 working in oncology and immunology. 3 oncology drugs already in the pharma market in China, one is marketed in the USA, pending approval in Europe. Finally, attractive pipeline and a healthy positive balance in the bank. Market value a mere 3 billion!
Yet, no news of ‘expression of interest’ for takeover (or merger) from bigger companies.
(Possibly, that is the only hope for long term holders)
Another achievement! Market response is as anticipated!! Nothing to be surprised at.
If approved by NMPA as therapy for the new indication, who will have marketing rights? AZN or HCM?
‘…..Naive patients …., does it mean as primary therapy?
It will be interesting to compare the assets/ pipeline/ number of scientific staff/ ongoing clinical studies of various drug candidates/ research and production facilities of HCM and the two companies that have been taken over.
What might the reasons for HCM not being (at least, until now) considered for takeover? Is it the “Grand” market value of 3 billion USD/ the pipeline unattractive??
application for approval for fru*****inib by the european medical agency was made in may/ june 2023. a positive outcome here in europe will be a major achievement for takeda and hcm and boost the income for both. that may, more likel,y encourage studies being conducted as primary therapy for other indications. hcm will become more noticeable in the pharma corporate market. question is how much longer will it take for ema’s decision to be announced?